Biological characteristics of side population cells in a self-established human ovarian cancer cell line

Wei,Zhentong; Lv,Shuang; Wang,Yishu; Sun,Meiyu; Chi,Guangfan; Guo,Jun; Song,Peiye; Fu,Xiaoyu; Zhang,Songling; Li,Yulin

doi:10.3892/ol.2016.4565

Biological characteristics of side population cells in a self-established human ovarian cancer cell line

Authors:
- Zhentong Wei
- Shuang Lv
- Yishu Wang
- Meiyu Sun
- Guangfan Chi
- Jun Guo
- Peiye Song
- Xiaoyu Fu
- Songling Zhang
- Yulin Li
View Affiliations

Affiliations: Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 13, 2016 https://doi.org/10.3892/ol.2016.4565
Pages: 41-48
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to establish an ovarian cancer (OC) cell line from ascites of an ovarian serous cystadenocarcinoma patient and investigate the biological characteristics of its side population (SP) cells. The OC cell line was established by isolating, purifying and subculturing primary cells from ascites of an ovarian serous cystadenocarcinoma patient (stage IIIc; grade 3). SP and non‑SP (NSP) cells were isolated by fluorescence‑activated cell sorting and cultured in serum‑free medium and soft agar to compare the tumorsphere and colony formation capacities. Furthermore, SP and NSP cell tumorigenesis was examined by subcutaneous and intraperitoneal injection of the cells to non‑obese diabetic/severe combined immune deficiency (NOD/SCID) mice. Drug resistance to cisplatin was examined by cell counting kit-8. The OC cell line was successfully established from ascites of an ovarian serous cystadenocarcinoma patient, which exhibited properties similar to primary tumors subsequent to >50 passages and >2 years of culture. The SP cell ratio was 0.38% in the OC cell line, and a similar SP cell ratio (0.39%) was observed when sorted SP cells were cultured for 3 weeks. Compared with NSP cells, SP cells exhibited increased abilities in differentiation and tumorsphere and colony formation, in addition to the formation of xenografted tumors and ascites and metastasis of the tumors in NOD/SCID mice, even at low cell numbers (3.0x103 cells). The xenografted tumors demonstrated histological features similar to primary tumors and expressed the ovarian serous cystadenocarcinoma marker CA125. In addition, SP cells demonstrated a significantly stronger drug resistance to cisplatin compared with NSP and unsorted cells, while treatment with verapamil, an inhibitor of ATP‑binding cassette transporters, potently abrogated SP cell drug resistance. In conclusion, the present study verified SP cells from an established OC cell line and characterized the cells with self‑renewal, differentiation, proliferation, tumorigenesis and stronger drug resistance capacities.

View Figures

View References

1	Pecorelli S, Favalli G, Zigliani L and Odicino F: Cancer in women. Int J Gynaecol Obstet. 82:369–379. 2003. View Article : Google Scholar : PubMed/NCBI
2	Ozols RF: Update on the management of ovarian cancer. Cancer J. 8(Suppl 1): S22–S30. 2002.PubMed/NCBI
3	Ozols RF: Treatment goals in ovarian cancer. Int J Gynecol Cancer. 15(Suppl 1): 3–11. 2005. View Article : Google Scholar : PubMed/NCBI
4	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X and Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell. 5:19–24. 2004. View Article : Google Scholar : PubMed/NCBI
6	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
7	Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 8:806–823. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
9	Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al: Identification of cells initiating human melanomas. Nature. 451:345–349. 2008. View Article : Google Scholar : PubMed/NCBI
10	Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J and Song E: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H and Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is amolecular determinant of the side-population phenotype. Nature Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
12	Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada K and Nakagata N: Regulation of oxidative stress by ATM isrequired for self-renewal of haematopoietic stem cells. Nature. 31:997–1002. 2004. View Article : Google Scholar
13	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
14	Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
15	Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
16	Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, MacLaughlin DT, Donahoe PK and Wei X: Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA. 109:2358–2363. 2012. View Article : Google Scholar : PubMed/NCBI
17	Christgen M, Geffers R, Ballmaier M, Christgen H, Poczkaj J, Krech T, Kreipe H and Lehmann U: Down-regulation of the fetal stem cell factor SOX17 by H33342: A mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem. 285:6412–6418. 2010. View Article : Google Scholar : PubMed/NCBI
18	Oates JE, Grey BR, Addla SK, Samuel JD, Hart CA, Ramani VA, Brown MD and Clarke NW: Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev. 18:1515–1522. 2009. View Article : Google Scholar : PubMed/NCBI
19	Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, et al: Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 132:2440–2450. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mas A, Cervelló I, Gil-Sanchis C, Faus A, Ferro J, Pellicer A and Simón C: Identification and characterization of the human leiomyoma side population as putative tumor-initiating cells. Fertil Steril. 98:741–751, e6. 2012. View Article : Google Scholar : PubMed/NCBI
21	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
22	Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D and Gu N: Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int. 35:227–234. 2011. View Article : Google Scholar : PubMed/NCBI
23	Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT and Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
24	Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
25	Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, et al: Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications. Blood. 117:4409–4419. 2011. View Article : Google Scholar : PubMed/NCBI
26	Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W, Tomlinson IP and Carter NP: Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res. 64:4817–4825. 2004. View Article : Google Scholar : PubMed/NCBI
27	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
28	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
29	Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
30	O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar : PubMed/NCBI
31	Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
32	Zhang SL, Wang YS, Zhou T, Yu XW, Wei ZT and Li YL: Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. Cytotechnology. 64:477–484. 2012. View Article : Google Scholar : PubMed/NCBI
33	Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65:3025–3029. 2005.PubMed/NCBI
34	Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133⁺ ovarian cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
35	Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006. View Article : Google Scholar : PubMed/NCBI
36	Burkert J, Otto WR and Wright NA: Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol. 214:564–573. 2008. View Article : Google Scholar : PubMed/NCBI
37	Kai K, D'Costa S, Yoon BI, Brody AR, Sills RC and Kim Y: Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer. 70:146–151. 2010. View Article : Google Scholar : PubMed/NCBI
38	Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V and Yamashita S: Characterization of side population in thyroid cancer cell lines: Cancer stem-like cells are enriched partly but not exclusively. Endocrinology. 148:1797–1803. 2007. View Article : Google Scholar : PubMed/NCBI
39	Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Rückauer KD and Beuschlein F: Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology. 149:1314–1322. 2008. View Article : Google Scholar : PubMed/NCBI
40	Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R, Wunder JS and Alman BA: Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 67:8216–8222. 2007. View Article : Google Scholar : PubMed/NCBI
41	Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, et al: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 10:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
42	Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
43	Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, et al: ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 123:2119–2130. 2013. View Article : Google Scholar : PubMed/NCBI
44	Januchowski R, Zawierucha P, Andrzejewska M, Ruciński M and Zabel M: Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother. 67:240–245. 2013. View Article : Google Scholar : PubMed/NCBI
45	Chen Y, Li D, Wang D, Liu X, Yin N, Song Y, Lu SH, Ju Z and Zhan Q: Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells. J Cell Biochem. 113:3643–3652. 2012. View Article : Google Scholar : PubMed/NCBI
46	Li XX, Dong Y, Wang W, Wang HL, Chen YY, Shi GY, Yi J and Wang J: Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev. 22:554–566. 2013. View Article : Google Scholar : PubMed/NCBI